Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511540 | 0.89 | CYP2C9 (0.60) | CYP2C9CYP1A2KMT2AMAPTTDP1 | |
| SCHEMBL3513141 | 0.89 | CYP2C9 (0.60) | CYP2C9CYP1A2KMT2AMAPTTDP1 | |
| SCHEMBL3515375 | 0.88 | CYP2C9 (0.56) | CYP2C9CYP1A2KMT2AMAPTTDP1 | |
| SCHEMBL3512989 | 0.88 | CYP2C9 (0.58) | CYP2C9CYP1A2KMT2AMAPTTDP1 | |
| SCHEMBL3513748 | 0.86 | CYP2C9 (0.48) | CYP2C9CYP1A2KMT2AMAPTTDP1 | |
| SCHEMBL3513265 | 0.86 | CYP2C9 (0.56) | CYP2C9CYP1A2KMT2AMAPTTDP1 | |
| SCHEMBL3512862 | 0.86 | CYP2C9 (0.56) | CYP2C9CYP1A2KMT2ALMNAFFAR4 | |
| SCHEMBL3515546 | 0.86 | LMNA (0.57) | CYP2C9CYP1A2KMT2AMAPTTDP1 | |
| SCHEMBL3513845 | 0.85 | CYP2C9 (0.55) | CYP2C9CYP1A2KMT2AMAPTTDP1 | |
| SCHEMBL3512980 | 0.84 | CYP2C9 (0.72) | CYP2C9CYP1A2KMT2AMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-11-04 | — | — | US | disclosed |
| EP-2005177-A1 | A HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | Tibotec Pharmaceuticals Ltd. (IE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113337-A1 | A HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113337-A1 | A HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | C1QBP, CD4, CHRM4 | CYP2C9 4489/4885CYP1A2 4221/4885KMT2A 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.